This study was undertaken to provide a better understanding of stereotactic body radiotherapy (SBRT) in nonoperable nonesmall-cell lung cancer with a largest tumor dimension of > 5 cm. A retrospective analysis was conducted on a prospective SBRT registry, with analysis of 41 patients. SBRT results in good local control and acceptable rates of distant control and treatment-induced toxicities in larger lung tumors. Background: Stereotactic body radiotherapy (SBRT) is a well-established treatment option for early stage nonesmallcell lung cancer (NSCLC) tumors < 5 cm. There is limited information on tumors > 5 cm. Patients and Methods: We performed retrospective data collection of patients enrolled onto a prospective SBRT registry study. Eligible patients for this study had node-negative NSCLC measuring > 5 cm in any dimension. Data from 41 patients were analyzed. Median patient age was 75 years, and median tumor size was 5.6 cm (range, 5.0-12.2 cm). Sixteen patients had squamous disease, 20 patients adenocarcinoma, and 1 mixed tumor; 4 patients had no biopsy. Median radiation dose per fraction was 50 Gy in 5 fractions. Radiation was prescribed to isodose line, median 66% (range, 50%-84%). Results: Before SBRT, 6 patients had previous chemotherapy and 7 patients had previous radiation. Median follow-up for all patients was 15.2 months (range, 0.56-48.1 months). At last follow-up, 16 patients were still alive, with a median follow-up of 16.1 months for surviving patients. The median survival was 17.5 months with 1-and 2-year survivals of 65% and 34%. Two patients (4.8%) had local failure, and 13 patients (31%) had distant failure. Four patients (9.8%) had acute toxicity, and 7 patients (17.1%) had late toxicity, including 2 (4.8%) grade 3 late toxicities. Conclusion: SBRT for tumors > 5 cm is effective, with good local control rates and acceptable toxicity. The main pattern of failure is distant, suggesting a possible role for systemic chemotherapy in these patients.
Introduction
The standard treatment for early stage lung cancers is surgical resection. For patients who are not candidates for surgery, stereotactic body radiotherapy (SBRT) has emerged as a potential treatment option. The seminal study regarding SBRT for early stage nonesmall-cell lung cancer (NSCLC) by Timmerman et al 1 enrolled nonoperable patients with peripheral T1-2N0M0 NSCLC < 5 cm. Although patients with T3 tumors (size > 5 cm) were eligible for the study, no patient with a tumor > 5 cm was actually enrolled. The study found a 3-year primary tumor control rate of 97.6%, and overall disease-free survival was 55.8% at 3 years. Multiple series have found SBRT to be safe and effective for patients with early stage disease 2-7 -possibly better than conventional radiotherapy interventions. 6 The literature on large-size lung tumors (> 5 cm) and SBRT treatments is scant; most of the research in this field has focused on smaller NSCLC tumors. Woody et al 8 reported on 40 patients with nonoperable NSCLC > 5 cm, and several series examined subsets of NSCLC > 3 cm. 7, 9 Larger tumors have been associated with more nonlocal failures and worse survival rates. 10, 11 Because of the paucity of the data and the existing need for research in this field, we analyzed our prospective SBRT database of NSCLC tumors > 5 cm.
Materials and Methods

Inclusion Criteria
This was a retrospective review of a prospectively maintained database. The study was approved by the local institutional review board (approval 1094EX). All cases of lung cancer were reviewed. Patients eligible for this analysis had NSCLC > 5 cm as measured in at least 1 dimension via computed tomographic (CT) scan. Patients were node negative (N0) based on imaging or biopsy of suspicious lymph nodes. All patients were treated at the MD Anderson Cancer Center at Cooper Hospital (Camden, NJ) between October 2008 and November 2015. Exclusion criteria included any lung tumors that were non-NSCLC.
Treatment
All patients were treated using CyberKnife (Accuray, Sunnyvale, CA). All patients had CT scans at the end of exhale and inhale for radiation planning; this could be done with or without contrast at the discretion of treating physician. For larger tumors visible in the projected X-ray images, the XSight lung technique was used to treat the patient by continuously monitoring the tumor movement. For the rest of the patients, 2 to 5 fiducials were implanted around the tumors and were used as the surrogate for tumor tracking (Synchrony technique).
All patients had gross tumor volume (GTV) contoured based on clinical examination, CT scans, and other images (typically positron emission tomography [PET] scans) when available. Planning target volume (PTV) was an expansion of the GTV and was usually around 5 mm in all directions. Peripheral tumors were treated on consecutive days, while central tumors were treated every other day. Treatments were prescribed to an isodose line. Organ-at-risk constraints were identical to those from recent cooperative group SBRT studies.
Follow-up
Patients were typically seen every 3 months for follow-up, which included a history and a physical examination. Chest CT scans were acquired 3 months after treatment, and if necessary, PET-CT scans were performed to confirm any suspicious lesions. Any toxicities that were suspected to be a result of the SBRT therapy were graded according to the National Cancer Institute Common Terminology for Adverse Events, version 3.0 (http://ctep.cancer.gov/). Evaluation of toxicities and of local and distant failure were evaluated on posttreatment visits.
Results
Patient and Tumor Characteristics
Forty-one patients met the inclusion criteria for this study. Our institutional standard for early stage NSCLC was surgical resection. Although the exact details for inoperability were not always recorded, all patients would have been medically unfit for surgery or refused surgical resection. Demographics and characteristics are listed in Table 1 . There were 20 male and 21 female subjects with a median age of 75 years. The median Karnofsky performance status at the time of SBRT treatment was 80 (range, 50-100). Prior chemotherapy had been administered to 6 patients (15%), while prior radiotherapy had been administered to 7 patients (17%). Four of the patients who had received previous radiotherapy had received thoracic radiation for previous lung cancer (median dose, 60 Gy). The median largest tumor dimension was 5.6 cm, with a range of 5 to 12.2 cm. Sixteen patients had a biopsy positive for adenocarcinoma and 20 positive for squamous-cell disease; 4 patients were unable to undergo a biopsy, and 1 had mixed NSCLC histology positive for adenocarcinoma and squamous-cell carcinoma. For patients without biopsy, the decision to proceed without tissue analysis was based on radiographic progression of lung lesion in a . The median percentage of isodose line was 66%, and all treatments were between 3 and 5 fractions. The median radiation dose was 50 Gy (range, 25-60 Gy). Nineteen patients (46%) were treated 50 Gy in 5 fractions, 10 patients (24%) were treated with 44 to 50 Gy in 4 fractions, 5 patients (12%) were treated with 40 to 45 in 5 fractions, 2 patients were treated with 54 to 60 in 3 fractions, 2 patients were treated with 25 Gy in 5 fractions, 2 patients were treated with 45 Gy in 3 fractions, and 1 patient was treated with 32 Gy in 4 fractions. Our institutional standard is to protect organs at risk above tumor coverage; in the event that organ-at-risk constraints could not be met, radiation dose could be decreased (This is why there was heterogeneity in dose prescriptions, as described above.).
The median follow-up was 15.2 months for all patients. Sixteen patients were alive at the time of analysis, with a median follow-up of 16.1 months. Median follow-up for deceased subjects was 12.4 months. Overall survival was 65% and 34% at 1 and 2 years, respectively (Figure 1) .
Of the 41 patients in our study, 26 patients experienced no disease recurrence (63.4%). Two (4.8%) of 41 patients had local failure. The size of the 2 tumors with local failure were 5 and 7.7 cm, respectively. PTV for local failure cases was 32.6 and 50.2 cm 3 compared to a median PTV of 87.2 cm 3 for the entire study population. Radiation dose for the 2 local failures included 1 patient treated 25 Gy in 5 fractions and 48 Gy in 4 fractions. Distant failure was noted in 13 patients (31.7%). Median maximal tumor diameter of patients experiencing distant failure was 5.6 cm, which is identical to the median diameter of the overall study population. Similarly, median PTV volume of these patients was not significantly different than the overall population. Of the distant failures, 30.8% of the tumors were peripherally located and 69.2% were centrally located. Histologic type was squamous cell for 5 subjects (38.5%) and adenocarcinoma for 7 (53.8%); 1 patient did not have identified tumor histology. 
Stereotactic Body Radiotherapy for NSCLC
Acute toxicity was noted in 4 patients (9.7%) ( Table 2 ). For patients with acute toxicity, the median largest tumor dimension was 5.1 cm compared to a median largest tumor dimension of 5.6 cm for the entire study population. Median PTV for acute radiation-induced toxicities was 62.3 cm 3 compared to 87.2 cm 3 for the entire study population. Seven patients (17.0%) had late radiation-induced toxicities (Table 3) , and 2 patients had grade 3 late toxicity (4.8%). The median largest tumor dimension for patients with late toxicity was 5.6 cm compared to a median largest tumor dimension of 5.6 cm for the entire study population. Median PTV for late radiationinduced toxicities was 802 cm 3 compared to 87.2 cm 3 for the entire study population. Three subjects had a centrally located tumor, and 4 subjects had a peripherally located tumor. Chest wall pain was typically managed with pain medication, while the patient with pneumonitis was managed with steroids. We looked at factors predictive for failure and toxicity, including tumor size, PTV volume, tumor location, isodose line, and histology. No factor was found to be predictive on subset analysis. Of the 7 patients with previous radiation, 4 had previous thoracic radiation.
Two of the 4 patients had late toxicity (1 grade 3 shortness of breath and 1 grade 2 chest wall pain).
Discussion
While there is mounting evidence on the outcomes of SBRT in < 5 cm primary lung tumors, 1-7 outcome on tumors > 5 cm remains underreported in the literature. 8, 12 We aimed to improve the knowledge regarding this subset. Our results are similar to other series. Woody et al 8 reported on 40 patients with medically inoperable NSCLC tumors > 5 cm; they found 91.2% local control at 18 months, which was similar to our local control rate of 95.2%; they also found a high rate of distant failure, with 32.5% of patients having distant failure, similar to our distant failure rate of 31.7%. The median follow-up in their study was 10.8 months, which is several months shorter than the median follow-up in our study. Our results and those of Woody et al 8 are similar to another published report on NSCLC > 3 cm. 9 Tumor histology (adenocarcinoma vs. squamous), location (peripheral vs. central), largest tumor dimension, and PTV all did not have any predictive value in identifying distant control. With only 2 Figure 2 Outcome and Target Size subjects identified as having local failure, few conclusions can be drawn regarding risk factors for local failure. These results are slightly worse compared to expected outcomes for NSCLC < 5 cm. (RTOG 0236 had 97.6% local control and 22.1% distant failure at 3 years. 1 ) It is not surprising that the larger tumors had worse outcomes; many series have shown that larger tumor dimensions and volumes correlate with worse outcomes. 10, 11, 13 Despite this, an increase in primary tumor size in our population did not appear to be predictive for worsening local or distant control (Figure 2 ). In both our series, as well as in series by others, the predominant pattern of failure was distant. On this basis, patients in this subset should be considered for post-SBRT chemotherapy. In an unplanned subset analysis, CALBG 9633 found improved outcomes in surgically resected NSCLC > 4 cm. 14 Further investigation is warranted to better understand the role adjuvant chemotherapy plays in modifying rates of distant failure in large primary lung tumors after SBRT. The results from our study suggest that SBRT therapy in large > 5 cm primary NSCLC tumors is associated with acceptable rates of grade 2 or higher therapy-associated toxicities, comparable to reports on tumors < 5 cm. This investigation aimed to advance our understanding of SBRT for primary NSCLC tumors (> 5 cm) as measured by survival, local and distant control, and treatment-induced toxicities. Our analysis offers guidance on using targeted radiotherapy in larger lung tumors. We found acceptable local control rates and toxicity rates with this treatment.
Conclusion
The results of this study suggest that SBRT for larger primary lung lesions (> 5 cm) is feasible, with acceptable local and distant failure rates. SBRT was well tolerated with minimal grade 2 or greater associated toxicities. Further investigation is warranted due to the potential benefit this treatment option could provide patients with large tumors. Also, given the high rate of distant failure, the role of adjuvant chemotherapy should be further explored for mitigating distant failure in this population.
Clinical Practice Points
We performed a retrospective review of a prospective SBRT database, analyzing 41 patients treated with SBRT for NSCLC > 5 cm. SBRT was associated with excellent local control rates (94.8%), no grade 4 or 5 toxicity, and a low rate (4.8%) of late grade 3 toxicity. Distant failure was the most common form of failure in this patient population (31%). Systemic chemotherapy may be considered after completion of SBRT.
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